.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average follow-up of 11 months, patients with metastatic intestinal growths that obtained biomarker-matched therapies based on circulating lump DNA profiling revealed a better scientific benefit than those receiving unmatched therapy.